About us

Mr. Paul Cassingham is a senior legal consultant at Eiger, a renowned independent law firm in Taiwan, with offices in Taipei and Shanghai. Before joining Eiger, Mr. Cassingham was a partner at several law firms in the U.S., Hong Kong, and Taiwan. Over the past 30 years, he represented many multinationals in the U.S., Europe, and other countries, in charge of legal affairs in Asia-Pacific, with customers spanning a wide range of fields, including medicine, consumer products, biotech, energy, electronics, chemicals, engineering, manufacturing, finance, real estate, and movie production.

 

Mr. Cassingham has been an active member of AmCham Taipei over the past 25 years, serving as its chairman during 1999-2000 and as chair of the Government Relations Committee now, in charge of AmCham Taipei's stance and policy direction on Taipei-U.S. economic/trade issues, including Taiwan's accession to WTO and Government Procurement Agreement (GPA), Taiwan-U.S. Trade and Investment Framework Agreement (TIFA), and Trans-Pacific Partnership (TPP).

 

Mr. Cassingham has publicized/delivered 50 papers/speeches and frequently accepted interviews by TV and radio-broadcast stations, commenting on foreign investments and Taiwan-U.S. political and economic/trade relationship, in addition to hosting "Business Review" talk show at Unique Satellite TV. He graduated from law school of Northwestern University and University of Michigan of the U.S.

With over 20 years of experience in bio-pharmaceutical development, Dr. Zhuan Gzhe-Ren specializes in the market development, manufacturing, technical process development, and bio-pharmaceutical plant design.
After obtaining a doctorate degree in Chemical Engineering from the Massachusetts Institute of Technology, Dr. Zhuan worked for Merck & Co., Inc., San Fu Chemical Co., (joint venture with US Air Products & Chemicals Inc.), Hoffmann-La Roche Ltd. US and Bristol-Myers Squibb Company. Then he served as general manager and chief executive at the R&D center, China Chemical & Pharmaceutical Co., Ltd.

Dr. Zhuan has abundant experience in bio-pharmaceutical industry, with such stints as independent director and consultant of technical process/strategy, bio-pharmaceutical plant design, and cGMP regulations. He was biotech consultant of Uni-President Enterprises Corp., chemical and medical consultant of Industrial Technology Research Institute, committee member of the MEMS program of National Chung-Shan Institute of Science & Technology, committee member of ICH Taiwan, committee member of the Center for Drug Evaluation Taiwan, committee member of the technical project, Ministry of Economic Affairs, and consultant of the bio-pharmaceutical development team, Ministry of Economic Affairs.

Dr. Shao-Hsuan Kao Drug obtained his Ph. D. in Science from Institute of Biochemistry and Molecular Biology, National Taiwan University. He has conducted postdoctoral research at Centers of Genomic Medicine, National Taiwan University Hospital and Institute of Biomedical Sciences, Academia Sinica. He joined a team to participate in the 4th WeWin Entrepreneurship Competition hold by Taiwan Industrial Bank (the former O-Bank) and the team came in second in the race. He also conducted the product development and functional activity tests for biotechnology companies, and serves as a consultant for Pingtung Agricultural Biotechnology Park.

Dr. Shao-Hsuan Kao is currently working at Chung Shan Medical University. He has been the director of the Industry Cooperation and Incubation Center of the Research and Development Office, the director of the Student Assistance Division of the affiliated hospital. The research interests are mainly focused on analyzing the effects of environmental bioaerosols on human immunoreactivity, exploring the molecular pathogenesis of allergens, and understanding the biological activities and mechanisms of natural molecules in anti-inflammatory and anti-tumor. Today, a total of more than 60 SCI papers have been published by Dr. Kao and his research team.

Yin-Hsong Hsu is a distinguished leader in Taiwan's technology and healthcare industries, with a career spanning over three decades. He currently serves as the President of Repurgenesis Co. Ltd., in addition to holding several other prominent roles. These include being a Visiting Professor at the College of Artificial Intelligence at National Yang Ming Chiao Tung University, and a Contract Chair Professor at Feng Chia University. He also maintains an affiliation with the Industrial Technology Research Institute as a Senior Distinguished Research Fellow and is an Adjunct Professor at his alma mater, National Yang Ming Chiao Tung University.

Dr. Hsu's journey is marked by his significant contributions to both the corporate and academic worlds. Over two decades at Acer Group, he played a pivotal role in software development and advanced technology R&D. From 2018 to 2023, he was the President of Acer Medical Inc., where he pioneered Taiwan's smart healthcare industry. His leadership culminated in a major achievement: securing Taiwan's first FDA-approved AI-based Software as a Medical Device (SaMD) for ophthalmology. This innovative solution has since been deployed in over 200 medical institutions, including 80% of Taiwan's major medical centers, and assists in the diagnosis of more than 300,000 diabetes patients each year.

A highly respected figure, Dr. Hsu's expertise in software development, artificial intelligence, and smart healthcare has been instrumental in bridging the gap between cutting-edge technology and medical practice. His work has not only revolutionized healthcare in Taiwan but also extended its reach to Southeast Asian markets, solidifying his reputation as a leader in the field.